Suvretta Capital and SR One Capital led a $100m Series D round in Avalyn Pharma.

Suvretta Capital, an investment firm, and SR One Capital, a venture capital firm, led a $100m Series D round in Avalyn Pharma, a clinical-stage biopharmaceutical company, with participation from T Rowe Price Associates, Piper Heartland Healthcare, Rivervest Venture, Novo Holdings, Suvretta Capital, F-Prime Capital, Perceptive Xontogeny Venture, Norwest Venture, TPG Biotechnology, Eventide Asset Management, HSQ, Wellington Management, Vida Ventures, Catalio Capital, Pivotal Bioventure, and Rock Springs. “Lyn and team are executing a clear growth strategy for Avalyn rooted in both clinical insight and operational excellence. On behalf of the entire Board, we’re proud of their patient-focused approach and commitment to innovation and scientific rigor, which positions this company to redefine the future of what’s possible for patients suffering from pulmonary fibrosis,” Jill Carroll, SR One and Avalyn Partner and Board Director.